跳至主要内容
临床试验/EUCTR2011-004016-29-IT
EUCTR2011-004016-29-IT进行中(未招募)不适用

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, DoseRanging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults with Active Psoriatic Arthritis

BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO0 个研究点目标入组 224 人开始时间: 2012年2月9日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
224

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Inadequate response to NSAID or non-biologic DMARD • Minimum of 3 swollen and 3 tender joints • Active psoriatic skin lesions over minimum 3% body surface area • hsCRP = 0.3 mg/dL • Subjects must have diagnosis of active PsA by Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 12 weeks prior to screening
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 213
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 11

排除标准

  • Previously received or currently receiving concomitant biologic therapy

研究者

相似试验